Analyst Price Target is $11.50
▲ +21.05% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Kadmon in the last 3 months. The average price target is $11.50, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 21.05% upside from the last price of $9.50.
Current Consensus is
The current consensus among 6 polled investment analysts is to hold stock in Kadmon. This rating has held steady since June 2021, when it changed from a Buy consensus rating.
Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics to address unmet medical need. The company's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. The firms late-stage product candidate KD025, which is an orally administered selective inhibitor of Rho-associated coiled-coil kinase engages in development for the treatment of inflammatory and fibrotic diseases. The firm's a pivotal clinical trial of KD025 is underway in chronic graft-versus-host disease (cGVHD), as well as a Phase 2 clinical trial in systemic sclerosis. It is also developing next-generation immuno-oncology therapies, specifically IL-15 containing fusion proteins, for the treatment of cancer. The company's lead I-O product candidate, KD033, is an anti-PD-L1/IL-15 fusion protein. Kadmon was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY.